<DOC>
	<DOC>NCT00504829</DOC>
	<brief_summary>The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.</brief_summary>
	<brief_title>Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia</brief_title>
	<detailed_description>This is a multicenter, randomized, double-blind, 12 week study with a 52-week open-label follow-up to evaluate the safety and efficacy of LCP-AtorFen (the combination of atorvastatin and fenofibrate) in the treatment of hyperlipidemia. After a wash-out phase, eligible patients will be randomized on a 1:1:1 ratio to either LCP-AtorFen, atorvastatin or fenofibrate for 12 weeks. After the completion of the 12-week phase, all eligible patients will be offered to receive open-label LCP-AtorFen for another 52 weeks.</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1. A diagnosis of dyslipidemia (nonHDLC &gt;130 mg/dL and Triglycerides &gt; or equal to 150 mg/dL and &lt; or equal to 500 mg/dL). 2. Subject may be currently on a statin or other lipidlowering therapy but must be willing and able to washout for 8 weeks if on a fibrate or highdose niacin, 6 weeks if on a statin or lowdose niacin per day, or 4 weeks if on a bile acid sequestrant, ezetimibe, or &gt;1000 mg of fish oil per day. 3. Other inclusion criteria might apply 1. TGs &gt; 500 mg/dL. 2. History of coronary heart disease (CHD), transient ischemic attacks, stroke or revascularization procedure in the six months prior. 3. Presence of an aortic aneurysm or resection of an aortic aneurysm within six months. 4. Poorly controlled diabetes mellitus (glycosylated hemoglobin &gt;8.0% )or diabetes mellitus requiring insulin therapy. 5. Known lipoprotein lipase impairment or deficiency or Apo CII deficiency or familial dysbetalipoproteinemia. 6. History of pancreatitis. 7. Known allergy or sensitivity to statins or fibrates. 8. Poorly controlled hypertension. 9. Other exclusion criteria might apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>LCP-AtorFen</keyword>
	<keyword>Non-HDL cholesterol</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>HDL cholesterol</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>